Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST‑segment elevation myocardial infarction

Yong,Huijuan; Wang,Xin; Mi,Lin; Guo,Lijun; Gao,Wei; Zhang,Yongzhen; Cui,Ming

doi:10.3892/etm.2013.1432

Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST‑segment elevation myocardial infarction

Authors:
- Huijuan Yong
- Xin Wang
- Lin Mi
- Lijun Guo
- Wei Gao
- Yongzhen Zhang
- Ming Cui
View Affiliations

Affiliations: Department of Cardiology, Peking University Third Hospital, Beijing 100191, P.R. China
Published online on: November 28, 2013 https://doi.org/10.3892/etm.2013.1432
Pages: 316-322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated the beneficial effect of statin loading prior to elective and early percutaneous coronary intervention (PCI), in which the ‘pleiotropic effects’ of statins may contribute to these clinical benefits. The aim of the present study was to examine the potential effects of atorvastatin loading prior to primary PCI on coronary endothelial function and inflammatory factors in patients with acute ST‑segment elevation myocardial infarction (STEMI). A total of 60 patients with STEMI were randomized into three groups: Loading dose (80 mg atorvastatin prior to PCI; n=20), regular dose (20 mg atorvastatin prior to PCI; n=20) and control (without atorvastatin prior to PCI; n=20). The plasma samples were collected prior to, and immediately, 6 and 24 h after PCI in all the patients. The plasma concentrations of endothelial nitric oxide synthase (eNOS), nitric oxide (NO), interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α) and intercellular adhesion molecule‑1 (ICAM‑1) were examined using ELISA. The plasma eNOS levels immediately and 24 h after PCI were significantly higher in the regular dose group compared with the other groups. However, there were no significant differences in the plasma eNOS concentration prior to and 6 h after PCI, or in the plasma NO concentration at any of the time‑points among the three groups. The plasma IL‑6 levels prior to PCI were significantly lower in the loading dose group compared with the other groups; however, there were no significant differences in the plasma concentration of IL‑6 following PCI or in the concentrations of TNF‑α and ICAM‑1 at any of the time‑points among the three groups. In conclusion, atorvastatin loading in patients with STEMI undergoing primary PCI may not have protective effects on endothelial function and the inflammatory reaction.

View Figures

View References

1	Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S and Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:1711–1718. 2001. View Article : Google Scholar
2	Briguori C, Colombo A, Airoldi F, et al: Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 25:1822–1828. 2004. View Article : Google Scholar
3	Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 350:1495–1504. 2004. View Article : Google Scholar : PubMed/NCBI
4	Chang SM, Yazbek N and Lakkis NM: Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv. 62:193–197. 2004. View Article : Google Scholar : PubMed/NCBI
5	de Lemos JA, Blazing MA, Wiviott SD, et al: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 292:1307–1316. 2004.
6	Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G and Di SG; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 110:674–678. 2004. View Article : Google Scholar
7	Mood GR, Bavry AA, Roukoz H and Bhatt DL: Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol. 100:919–923. 2007. View Article : Google Scholar : PubMed/NCBI
8	Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A and Di SG: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 49:1272–1278. 2007. View Article : Google Scholar
9	Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B and Colombo A: Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 54:2157–2163. 2009. View Article : Google Scholar
10	Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G and Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 54:558–565. 2009.
11	Celik T, Kursaklioglu H, Iyisoy A, Kose S, Kilic S, Amasyali B, Kardesoglu E and Isik E: The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis. 16:321–326. 2005. View Article : Google Scholar
12	Ishii H, Ichimiya S, Kanashiro M, Aoyama T, Ogawa Y, Murakami R, Amano T, Naruse K, Matsubara T and Murohara T: Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther. 28:1812–1819. 2006. View Article : Google Scholar
13	Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K and Fujii K: Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 27:534–539. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lev EI, Kornowski R, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Battler A and Assali A: Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 103:165–169. 2009. View Article : Google Scholar
15	Garot P, Bendaoud N, Lefevre T and Morice MC: Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock. EuroIntervention. 6:350–355. 2010. View Article : Google Scholar
16	Kim JS, Kim J, Choi D, et al: Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 3:332–339. 2010. View Article : Google Scholar
17	Hahn JY, Kim HJ, Choi YJ, et al: Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 162:1026–1033. 2011. View Article : Google Scholar
18	Li W, Fu X, Wang Y, et al: Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 122:195–202. 2012. View Article : Google Scholar
19	Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Wijns W, Kolh P, Danchin N, et al: Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 38(Suppl): S1–S52. 2010. View Article : Google Scholar
20	Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 51:6061983. View Article : Google Scholar : PubMed/NCBI
21	TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
22	van ‘t HAW, Liem A, de Boer MJ and Zijlstra F: Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 350:615–619. 1997.
23	Ignarro LJ, Buga GM, Wood KS, Byrns RE and Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 84:9265–9269. 1987. View Article : Google Scholar : PubMed/NCBI
24	Radomski MW, Rees DD, Dutra A and Moncada S: S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 107:745–749. 1992. View Article : Google Scholar : PubMed/NCBI
25	Garg UC and Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1774–1777. 1989. View Article : Google Scholar
26	Kubes P, Suzuki M and Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 88:4651–4655. 1991. View Article : Google Scholar : PubMed/NCBI
27	Gauthier TW, Scalia R, Murohara T, Guo JP and Lefer AM: Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1652–1659. 1995. View Article : Google Scholar : PubMed/NCBI
28	Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP and Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:488–493. 1995. View Article : Google Scholar : PubMed/NCBI
29	Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC and Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:481–487. 1995. View Article : Google Scholar : PubMed/NCBI
30	Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R and Lefer DJ: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:178–184. 1999. View Article : Google Scholar : PubMed/NCBI
31	Wassmann S, Faul A, Hennen B, Scheller B, Bohm M and Nickenig G: Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 93:e98–e103. 2003. View Article : Google Scholar : PubMed/NCBI
32	Laufs U, La Fata V, Plutzky J and Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1129–1135. 1998. View Article : Google Scholar : PubMed/NCBI
33	Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI and Edelman ER: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 108:512–515. 2003. View Article : Google Scholar : PubMed/NCBI
34	Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G and Voelker W: Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J. 145:693–699. 2003. View Article : Google Scholar : PubMed/NCBI
35	Gomes WJ and Buffolo E: Coronary stenting and inflammation: implications for further surgical and medical treatment. Ann Thorac Surg. 81:1918–1925. 2006.PubMed/NCBI
36	Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, D’Ambrosio A, Covino E and Di SG: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 48:1560–1566. 2006.
37	Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, Mates M and Vojacek J: The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem. 246:45–50. 2003. View Article : Google Scholar : PubMed/NCBI